Glial fibrillary acidic protein is a major target of glycoxidative and lipoxidative damage in Pick's disease

Journal of Neurochemistry

Volumn 99, Issue 1, 2006, Pages 177-185

  Muntane G ^a   Dalfo E ^a   Martinez A ^a   Rey, M J ^a   Avila, J ^b   Perez M ^b   Portero, M ^c   Pamplona, R ^c   Ayala, V ^c   Ferrer, I ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c UNIVERSITY OF LLEIDA   (Spain)

Author keywords

Glial fibrillary acidic protein; Glycoxidation; Hydroxy 2 nonenal; Lipoxidation; Oxidative stress; Pick's disease

Indexed keywords

4 HYDROXYNONENAL; ADVANCED GLYCATION END PRODUCT; GLIAL FIBRILLARY ACIDIC PROTEIN; MALONALDEHYDE; N CARBOXYETHYLLYSINE; N CARBOXYMETHYLLYSINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CASE REPORT; CONTROLLED STUDY; FEMALE; FRONTAL CORTEX; GEL ELECTROPHORESIS; HUMAN; HUMAN TISSUE; MALE; NIEMANN PICK DISEASE; NUCLEOTIDE SEQUENCE; OCCIPITAL CORTEX; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PICK PRESENILE DEMENTIA; PRIORITY JOURNAL; PROTEOMICS; WESTERN BLOTTING;

ALDEHYDES; AUTOPSY; BRAIN; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCOSYLATION; HUMANS; LIPIDS; MAGNETIC RESONANCE IMAGING; MASS SPECTROMETRY; NERVE TISSUE PROTEINS; OXIDATIVE STRESS; PICK DISEASE OF THE BRAIN; REFERENCE VALUES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33748685003     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2006.04032.x     Document Type: Article

References (40)

1. Aksenov M. Y., Aksenova M. V., Payne R. M., Smith C. D., Markesbery W. R. and Carney J. M. (1997) The expression of creatine kinase isoenzymes in neocortex of patients with neurodegenerative disorders: Alzheimer's and Pick's disease. Exp. Neurol. 146, 458-465.
2. Aksenova M. V., Aksenov M. Y., Payne R. M., Trojanowski J. Q., Schmidt M. L., Carney J. M., Butterfield D. A and Markesbery W. R. (1999) Oxidation of cytosolic proteins and expression of creatine kinase B in frontal lobe in different neurodegenerative disorders. Dement. Geriatr. Cogn. Disord. 10, 158-165.
3. Arai T., Ikeda K. and Akiyama H. (2001) Distinct isoform of tau aggregated in neurons and glial cells in brains of patients with Pick's disease, corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol. 101, 167-173.
4. Arai T., Ikeda K., Akiyama H., Tsuchiya K, Iritani S., Ishiguro K., Yagashita S., Oda T., Odawara T. and Iseki E. (2003) Different immunoreactivities of the microtubule-binding region of tau and its molecular basis in brains from patients with Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol. 105, 489-498.
5. Atzori C., Ghetti B., Piva R., Srinivasan A. N., Zolo P., Delisle M. B., Mirra S. S. and Migheli A. (2001) Activation of JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis. J. Neuropathol. Exp. Neurol. 60, 1190-1197.
6. Baydas G., Tuzcu M., Yasar A. and Baydas B. (2004) Early changes in glial reactivity and lipoid peroxidation in diabetic rat retina: effects of melatonin. Acta Diabetol. 41, 123-128.
7. Beal M. F. (2002) Oxidatively modified proteins in aging and disease. Free Radic. Biol. Med. 32, 797-803.
8. Bergeron C., Morris H. R. and Rossor M. (2003) Pick's disease, in Neurodegeneration. The Molecular Pathology of Dementia and Dementia with Movement Disorders (Dickson, D., ed.), pp. 124-131. ISN. Neuropath Press, Basel.
9. Broe M., Kril J. and Halliday G. M. (2004) Astrocytic degeneration relates to the severity of disease in frontotemporal dementia. Brain 127, 2214-2220.
10. Buée L., Bussière T., Buée-Scherrer V., Delacourte A. and Hof P. R. (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Rev. 33, 95-130.
11. Butterfield D. A. and Kanski J. (2001) Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech. Ageing Dev. 122, 945-962.
12. Castellani R., Smith M. A., Richey P. L., Kalaria R., Gambetti P. and Perry G. (1995) Evidence for oxidative stress in Pick disease and corticobasal degeneration. Brain Res. 696, 268-271.
13. Choi J., Levey A. I., Weintraub S. T., Rees H. D., Gearing M., Chin L. S. and Li L. (2004) Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopatic Parkinson's disease and Alzheimer's disease. J. Biol. Chem. 279, 13 256-13 264.
14. Choi J., Rees H. D., Weintraub S. T., Levey A. I., Chin L. S. and Li L. (2005) Oxidative modifications of Cu,Zn-superoxide dismutase assocaited with Alzheimer and Parkinson diseases. J. Biol. Chem. 280, 11 648-11 655.
15. Dalfó E., Portero-Otin M., Ayala V., Martinez A., Pamplona R. and Ferrer I. (2005a) Evidence of oxidative stress in neocortex in incidental Lewy body disease. J. Neuropathol. Exp. Neurol. 64, 816-830.
16. Dalfó E., Rodríguez A., Albasanz J. L., Martin M. and Ferrer I. (2005b) Abnormal group I metabotropic glutamate receptor expression and signaling in the frontal cortex in Pick's disease. J. Neuropathol. Exp. Neurol. 64, 638-647.
17. Dickson D. (1998) Pick's disease. A modern approach. Brain Pathol. 8, 339-354.
18. Eng L. F., Ghirnikar R. S. and Lee Y. L. (2000) Glial fibrillary acidic protein: GFAP thirty-one years (1969-2000). Neurochem. Res. 25, 1439-1451.
19. Ferrer I., Blanco R., Carmona M. and Puig B. (2001) Phosphorylated mitogen-activated protein kinase (MAP/ERK-P), protein kinase of 38 kDa (p38-P), and stress-activated protein kinase (SAPK/JNKP), and calcium/calmodulin- dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies. J. Neural. Transm. 108, 1397-1415.
20. Ferrer I., Gomez-Isla T., Puig B., Freixes M., Ribe E., Dalfó E. and Avila J. (2005) Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Curr. Alzheimer Res. 2, 3-18.
21. Fujita K., Yamauchi M., Matsui T., Titani K., Takahashi H., Kato T., Isomura G., Ando M. and Nagata Y. (1998) Increase of glial fibrillary acidic protein fragments in the spinal cord of motor neuron degeneration mutant mouse. Brain Res. 785, 31-40.
22. Gray B. C., Skipp P., O'Connor V. M. and Perry V. H. (2006) Increased expression of glial fibrillary acidic protein fragments and μ-calpain activation within the hippocampus of prion-infected mice. Biochem. Soc. Trans. 34, 51-54.
23. Hartzler A. W., Zhu X., Siedlak S. L., Castellani R. J., Avila J., Perry G. and Smith M. A. (2002) The p38 pathway is activated in Pick disease and progressive supranuclear palsy: a mechanistic link between mitogen pathways, oxidative stress, and tau. Neurobiol. Aging 23, 855-859.
24. Hodges J. R., Davies R. R., Xuereb J. H., Casey B., Broe M., Bak T. H., Kril J. J. and Halliday G. M. (2004) Clinicopathological correlates in frontotemporal dementia. Ann. Neurol. 56, 399-406.
25. Kaneko K., Nakamura A., Yoshida K., Kametani F, Higuchi K. and Ikeda S. (2002) Glial fibrillary acidic protein is greatly modified by oxidative stress in aceruloplasminemia brain. Free Radic. Res. 36, 303-306.
26. Kimura T., Ikeda K., Takamatsu J., Miyata T., Sobue G., Miyakawa T. and Horiuchi S. (1996) Identification of advanced glycation end products of the Maillard reaction in Pick's disease. Neurosci. Lett. 219, 95-98.
27. King M. E., Ghoshal N., Wall J. S., Binder L. I. and Ksiezak-Reding H. (2001) Structural analysis of Pick's disease derived and in vitro-assembled tau filaments. Am. J. Pathol. 158, 1481-1490.
28. Komori T. (1999) Tau-positive glial inclusions in progressive supranuclear palsy, corticobasal degeneration and Pick's disease. Brain Pathol. 9, 663-679.
29. Korolainen M. A., Auriola S., Nyman T. A., Alafuzoff I. and Pirttila T. (2005) Proteomic analysis of glial fibrillary acidic protein in Alzheimer's disease and aging brain. Neurobiol. Dis. 20, 858-870.
30. Krapfenbauer K., Engidawork E., Cairns N., Fountoulakis M. and Lubec G. (2003) Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders. Brain Res. 967, 152-160.
31. Kril J. J., MacDonald V., Patel S., Png F., Png F. and Halliday G. M. (2005) Distribution of brain atrophy in behavioral variant frontotemporal dementia. J. Neurol. Sci. 232, 83-90.
32. McKhann G. M., Albert M. S., Grossman M., Miller B, Dickson D. and Trojanowski J. Q. (2001) Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch. Neurol. 58, 1803-1809.
33. Montine K. S., Kim P. J., Olson S. J., Markesbery W. R. and Montine T. J. (1997) 4-Hydroxy-2-nonenal pyrrole adducts in human neurodegenerative diseases. J. Neuropathol. Exp. Neurol. 56, 866-871.
34. Pamplona R., Dalfó E., Ayala V., Bellmunt M. J., Prat J., Ferrer I. and Portero-Otin M. (2005) Proteins in human cortex are modified by oxidation, glycoxidation, and lipoxidation. J. Biol. Chem. 280, 21 522-21 530.
35. Perry G., Nunomura A., Hirai K. et al. (2002) Is oxidative damage the fundamental pathogenic mechanism of Alzheimer and other neurodegenerative diseases? Free Radic. Biol. Med. 33, 1475-1479.
36. Puig B., Viñals F. and Ferrer I. (2004) Active stress kinase p38 enhances and perpetuates abnormal tau phosphorylation and deposition in Pick's disease. Acta Neuropathol. 107, 185-189.
37. Sasaki N., Fukatsu R., Tsuzuki K. et al. (1998) Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am. J. Pathol. 153, 1149-1155.
38. Sultana R., Boyd-Kimball D., Fai Poon H., Cai J., Pierce W. M., Klein J. B., Merchant M., Markesbery W. R. and Butterfield D. A. (2005) Redox proteomics of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: An approach to understand pathological and biochemical alterations in AD. Neurobiol. Aging in press.
39. Zarkovic K. (2003) 4-Hydroxynonenal and neurodegenerative diseases. Mol. Aspects Med. 24, 293-303.
40. Zhukareva V., Mann D., Pickering-Brown S. et al. (2002) Sporadic Pick's disease: a tauopathy characterized by a spectrum of pathological tau isoforms in gray and white matter. Ann. Neurol. 51, 730-739.